Huntington's disease is an autosomal dominant disease associated with a mutation in the gene encoding huntingtin (Htt) leading to expanded polyglutamine repeats of mutant Htt (mHtt) that elicit oxidative stress, neurotoxicity, and motor and behavioural changes 1 . Huntington's disease is characterized by highly selective and profound damage to the corpus striatum, which regulates motor function. Striatal selectivity of Huntington's disease may reflect the striatally selective small G protein Rhes binding to mHtt and enhancing its neurotoxicity 2 . Specific molecular mechanisms by which mHtt elicits neurodegeneration have been hard to determine. Here we show a major depletion of cystathionine c-lyase (CSE), the biosynthetic enzyme for cysteine, in Huntington's disease tissues, which may mediate Huntington's disease pathophysiology. The defect occurs at the transcriptional level and seems to reflect influences of mHtt on specificity protein 1, a transcriptional activator for CSE. Consistent with the notion of loss of CSE as a pathogenic mechanism, supplementation with cysteine reverses abnormalities in cultures of Huntington's disease tissues and in intact mouse models of Huntington's disease, suggesting therapeutic potential.
CSE is a principal generator of cysteine from cystathionine 3, 4 . Cystathionine is formed by cystathionine b-synthase (CBS) by condensing homocysteine and serine. CSE, CBS and 3-mercaptopyruvate sulphurtransferase use cysteine to generate the major gasotransmitter hydrogen sulphide (H 2 S) [3] [4] [5] . It was previously believed that CSE is restricted to peripheral tissues, whereas CBS is the principal generator of H 2 S in the brain 6 . We detected substantial CSE in brain lysates, implying a role for the enzyme in the brain (Fig. 1a, b) . In characterizing CSE-deleted mice 7 we noted abnormal hindlimb clasping and clenching reminiscent of mouse models of Huntington's disease, which prompted an exploration of CSE in Huntington's disease (Fig. 1c) . In a striatal cell line Huntington's disease model containing 111 glutamine repeats, STHdh Q111/Q111 (Q111), CSE protein levels were markedly decreased compared with control STHdh
Q7/Q7
(Q7) cells harbouring seven glutamine repeats (Fig. 1d, e) . Brains of R6/2 mice with Huntington's disease 8 also showed decreased CSE levels in the striatum, cortex, hippocampus, hypothalamus and brainstem, but not in the cerebellum (Fig. 1f, g ). To explore the generality of findings with R6/2 mice, we examined the Q175 mouse model of Huntington's disease 9 . Like the R6/2 mice, striata of the Q175 mice had diminished CSE levels (Fig. 1h, i) . In brains of humans with Huntington's disease, CSE levels were profoundly reduced in the striatum (Fig. 1j-m) , moderately diminished in the cerebral cortex and not altered in the cerebellum (Fig. 1l) , paralleling the relative susceptibility of these brain regions to damage by Huntington's disease. Clinical staging revealed a progressive depletion of CSE with increasing severity of the disease (Fig. 1l, m) . The depletion of CSE in Huntington's disease is not secondary to neurodegeneration. Thus, CSE levels were unaltered in post-mortem brain samples of patients with other neurodegenerative diseases: advanced amyotrophic lateral sclerosis, multiple sclerosis and spinocerebellar ataxia (Extended Data Fig. 1 ). In liver and pancreatic lysates of R6/2 mice, CSE levels were diminished to a similar extent to that in brain (Fig. 1n, o) . CSE generates both cysteine and H 2 S (Fig. 2a) . In striatal Q111 cells we observed a diminished formation of both H 2 S (Fig. 2b) and cysteine (Fig. 2c) . Cysteine-free diets are lethal to CSE-deleted mice 10, 11 , and CSE deficiency of Q111 cells was associated with cytotoxicity in the absence of cysteine (Fig. 2d) . On cysteine-free medium, 80% of Q111 cells die with only modest cell loss in Q7 cells. Supplementation with L-cysteine reversed the lethality (Fig. 2d) , as did overexpression of CSE (Fig. 2e) . Thus, the CSE depletion in Huntington's disease cells renders them hypersensitive to lethality associated with cysteine deprivation. Cysteine levels and H 2 S generation were diminished in striata of R6/2 mice (Fig. 2f, g ), and CSE activity was reduced in striata of Q175 mice (Fig. 2h) .
How does Huntington's disease elicit CSE depletion? The loss of cytosolic CSE could reflect the translocation of CSE to insoluble aggregates, which occurs in Huntington's disease 12, 13 . However, in Q111 cells CSE was depleted to similar extents in supernatant and particulate fractions (Fig. 3a) . CSE is probably not depleted by proteasomal enzymes, because the proteasomal inhibitor MG132 failed to elevate the very low levels of CSE in Q111 cells (Fig. 3b) .
Might depletion of CSE occur at a transcriptional level? Consistent with this possibility, analysis by PCR with reverse transcription (RT-PCR) revealed a marked decrease in mRNA levels for CSE in Q111 cells (Fig. 3c, d ). Moreover, reporter gene assays revealed substantially reduced CSE promoter activity in Q111 cells (Fig. 3e) . Thus, CSE transcription in Huntington's disease is evidently impaired at the level of transcriptional regulation. mHtt can elicit toxicity by disrupting transcriptional processes 14, 15 : it has been reported 16 that mHtt binds to and inhibits specificity protein 1 (Sp1), a known transcription factor for CSE 17, 18 . Overexpression of both Sp1 and its co-activator transcription initiation factor TFIID subunit 4 (TAF4) rescued the diminished messenger RNA and protein levels of CSE in Q111 cells ( Fig. 3f-h ) and improved growth in cysteine-free growth medium (Fig. 3i) . Thus, CSE depletion in Huntington's disease seems to reflect an inhibition of Sp1 by mHtt, leading to decreased CSE transcription.
Huntington's disease is associated with heightened oxidative stress and mitochondrial dysfunction 19 , and CSE has a function in mitochondrial homeostasis 20 . To assess whether CSE depletion elicits oxidative and mitochondrial stress, we treated wild-type and Cse 2/2 mice with 3-nitropropionic acid, a mitochondrial toxin that inhibits the complex II enzyme succinate dehydrogenase 21 . Treatment with 3-nitropropionic acid causes mitochondrial dysfunction and oxidative stress, thereby damaging striatal tissue and mimicking Huntington's disease 22 . Cse 2/2 mice were highly susceptible to 3-nitropropionic acid, showing elevated levels of protein carbonylation and nitration in the striatum and cortex (Extended Data Fig. 2 ). In addition, striatal Q111 cells showed greater susceptibility to hydrogen peroxide stress, and overexpressing CSE increased their resistance to H 2 O 2 ( Fig. 4a) . If the pathophysiology of Huntington's disease reflects, at least in part, CSE depletion, we might predict neurobehavioural aberrations in CSE deleted mice. Cse 2/2 mice showed impaired rotarod performance (Fig. 4b) . Cse 1/2 heterozygous mice also showed impaired motor functions, although not as severe as in the homozygous Cse 2/2 mice (Fig. 4b) .
By what molecular mechanisms might CSE exert cytoprotection? CSE is a major generator of cysteine, which is a building block for proteins and the antioxidant glutathione. In addition, cysteine is a precursor of H 2 S, which signals by attaching a thiol group to target proteins, a process termed sulphydration; this process typically activates enzymes, some of which are involved in cytoprotection 3, 23, 24 . For instance, H 2 S sulphydrates parkin to stimulate its catalytic activity, which provides striatal neuroprotection relevant to Parkinson's disease 25 . H 2 S also sulphydrates Keap1 (ref. 26 ), a repressor of the transcription factor Nrf2, which regulates several enzymes of the antioxidant defence pathway. In addition, H 2 S influences several cytoprotective pathways 27 . It is unclear whether the pathophysiological influences of CSE depletion in Huntington's disease reflect its role in generating cysteine or H 2 S. It is conceivable that treatment with H 2 S donors will be beneficial in treating Huntington's disease.
The ability of CSE and cysteine to reverse oxidative stress and lethality in Huntington's disease cells suggests that cysteine supplementation might be beneficial in treating Huntington's disease. Cysteine deficiency Patient samples Normal
Cerebellum Cortex f, Expression of CSE is decreased significantly in all brain regions of 13-week-old R6/2 mice analysed except in the cerebellum. g, Relative quantification of f. n 5 6 (means 6 s.e.m.) for cortex, striatum and cerebellum; n 5 3 (means 6 s.e.m.) for other regions; ***P , 0.001; **P , 0.01; NS, not significant. h, Expression of CSE is decreased in striata of Q175 mice. i, Quantification of h. n 5 3 (means 6 s.e.m.); ***P , 0.001. j, Post-mortem striatal brain samples (P1-P6) from patients with Huntington's disease show a decrease in CSE expression. k, Relative quantification of j. n 5 5 (means 6 s.e.m.) for controls; n 5 6 (means 6 s.e.m.) for samples from patients with Huntington's disease (HD); ***P , 0.001. l, CSE depletion is increased with the severity of the disease. C1 and C2 are controls; HD1-HD4 are samples from patients with Huntington's disease. m, Relative quantification of HD grades. n 5 3 (means 6 s.e.m.) for HD2; n 5 4 (means 6 s.e.m.) for normal, HD3 and HD4; *P , 0.05 (control versus HD2 and HD2 versus HD3); ***P , 0.001 (control versus HD4). n, CSE expression is decreased in the liver and pancreas. o, Relative quantification of n. n 5 3 (means 6 s.e.m.); ***P , 0.001. Figure 3 | CSE is depleted at the transcriptional level in Huntington's disease. a, CSE is not sequestered in the insoluble pellet fraction by mutant huntingtin. b, CSE is not differentially degraded in Q7 and Q111 cells after treatment with the proteasome inhibitor MG132. c, CSE mRNA is decreased in Q111 cells, as revealed by RT-PCR using b-actin as the internal control. d, Reduction of CSE expression in Q111 cells verified by real-time quantitative PCR. n 5 3 (means 6 s.e.m.); ***P , 0.001. e, CSE promoter activity is repressed in Q111 cells as revealed by luciferase assays using a CSE-luc reporter construct and an endogenous internal control. n 5 4 (means 6 s.e.m.); ***P , 0.001. f, Overexpression of the transcription factor Sp1 and its co-activator TAF4 rescues CSE expression. Empty vector controls are denoted by C. g, Relative quantification of f. n 5 3 (means 6 s.e.m.); **P , 0.01. h, Overexpression of Sp1 and TAF4 elevates CSE transcript levels as revealed by quantitative PCR. n 5 3 (means 6 s.e.m.); **P , 0.01. i, Overexpression of Sp1/TAF4 rescues lethality of Q111 cells in cysteine-free media as measured by the MTT assay. n 5 3 (means 6 s.e.m.); ***P , 0.001.
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has been implicated in oxidative stress and ageing 28 . Cystamine, the decarboxylated derivative of cystine (the disulphide of cysteine) confers neuroprotection in mouse models of Huntington's disease and increases cysteine levels in the brain 29 . Treating R6/2 mice with N-acetylcysteine (a stable precursor of cysteine) in their drinking water along with a cysteine-enriched diet delayed the onset of motor abnormalities such as hindlimb clasping (Fig. 4c and Supplementary Videos 1-3 ), rotarod performance ( Fig. 4d ) and grip strength (Fig. 4e) . Decreases in brain weight and striatal were partly reversed by treatment with cysteine ( Fig. 4f-h) , and survival was enhanced (Fig. 4i) .
Although many molecular targets of mHtt have been described, specific mechanisms that underlie Huntington's disease neurotoxicity have been hard to determine. It has been reported 16 that binding of mHtt to the transcriptional activator Sp1 mediates neurotoxicity by diminishing Sp1 activity. We propose that inhibition by mHtt of Sp1's transcriptional activation of CSE accounts for CSE depletion in Huntington's disease and associated neurological deficits. This CSE model of Huntington's disease is supported by the therapeutic effects of cysteine and Nacetylcysteine in mice with Huntington's disease. Our findings imply that N-acetylcysteine supplementation may be beneficial in treating diseases involving impaired reverse transsulphuration and oxidative stress.
METHODS SUMMARY
Assays of H 2 S and cysteine were conducted as described previously, with minor modifications 7, 20 . For the H 2 S assay, tissue and cells were lysed in ice-cold 50 mM potassium phosphate buffer pH 6.8, containing 0.1% Triton X-100. Total protein (1 mg) was incubated with 10 mM L-cysteine, 15 mM pyridoxal 5-phosphate in tightly sealed vials flushed with nitrogen, and the reaction was incubated for 4 h at 37 uC in a total volume of 250 ml. Next, 125 ml of 1% zinc acetate and 2.5 ml of 10 M NaOH were added to the vials and shaken at 25 uC for 1 h to ensure trapping of H 2 S released from the mixture. This was followed by the addition of 0.5 ml of distilled water and 0.1 ml of 20 mM N,N-dimethyl-p-phenylenediamine sulphate in 7.2 M HCl, immediately followed by the addition of 30 mM FeCl 3 N6H 2 O in 1.2 M HCl. The absorbance of the resulting product was measured at 670 nm. The Sp1 and TAF4 plasmid constructs were gifts from D. Krainc and harboured the respective genes under the CMV promoter, with a Myc tag and a haemagglutinin tag, respectively, for expression in mammalian cells.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. ). c, Cysteine supplementation delays motor symptoms in R6/2 mice. Mice were placed on regular diet or a cysteine-supplemented diet along with 20 mM N-acetylcysteine in the drinking water, and clasping phenotype was monitored. n 5 8 (means 6 s.e.m.); ***P , 0.001. See also Supplementary Videos 1-3. d, Cysteine supplementation improves performance on an accelerating rotarod in R6/2 mice. n 5 8 (means 6 s.e.m.) for WT; n 5 6 (means 6 s.e.m.) for R6/2; n 5 7 (means 6 s.e.m.) for R6/2 1 cysteine; *P , 0.05. e, Grip strength is improved in R6/2 mice placed on a cysteine-supplemented diet. *P , 0.05. f, Decrease in brain masses of R6/2 mice is ameliorated by cysteine treatment. g, Striatal atrophy is decreased in R6/2 mice treated with cysteine as assessed by Nissl staining of coronal sections of the brain. h, Striatal volume of R6/2 mice on a cysteine supplemented diet is larger than in the untreated R6/2 mice. n 5 3 (means 6 s.e.m.) for WT, n 5 4 (means 6 s.e.m.) for untreated R6/2 mice and R6/2 mice treated with cysteine. *P , 0.05. i, Cysteine supplementation prolongs survival in R6/2 mice (Kaplan-Meier analysis). R6/2 mice (n 5 7 per group) were treated as in f, and survival in weeks was monitored. Statistical analysis was conducted with the log-rank (Mantel-Cox) test; P 5 0.004.
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